Patients with diabetic peripheral neuropathy taking L-methylfolate, pyridoxal-5'-phosphate, and methylcobalamin (MPM) had lower all-cause hospitalization risk and healthcare costs than patients not taking MPM.
Rolin L. Wade, RPh, MS
Advertisement
Articles by Rolin L. Wade, RPh, MS
Advertisement
Latest Updated Articles
- Impact of L-Methylfolate Combination Therapy Among Diabetic Peripheral Neuropathy Patients
Published: October 17th 2012 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Environmental Factors Could Influence Type 1 Diabetes Risk in Children Through Epigenetic Changes
3
Less Common Pneumococcal Serotypes Cause More Severe Community-Acquired Pneumonia
4
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
5
